SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDM

[ACCESSWIRE]

NEW YORK, NY / ACCESSWIRE / October 13, 2023 / Pomerantz LLP is investigating claims on behalf of investors of Tandem Diabetes Care, Inc. ("Tandem" or the "Company") (NASDAQ:TNDM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

The investigation concerns whether Tandem and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On November 2, 2022, Tandem disclosed in a filing with the U.S. Securities and Exchange Commission and on a related earnings call that the Company had revised its 2022 sales forecast sharply downward, from previous guidance in the range of $835 million to $845 million, to a range of only $800 million to $805 million. Explaining the revised guidance, Tandem cited increased competition in the diabetes care sector, complications due to the COVID pandemic, and macroeconomic factors such as inflation.

On this news, Tandem's stock price fell $14.57 per share, or 28.38%, to close at $36.77 per share on November 3, 2022.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

SOURCE: Pomerantz LLP